Carlson; Jeffrey C.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Carlson; Jeffrey C..The latest application filed is for "compositions and methods for inhibiting gene expression of hif2alpha".

Company Profile

2.14.14

Carlson; Jeffrey C. - Madison WI
Carlson; Jeffrey C - Madison WI

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha App 20210180066 - Wong; So ; et al.	2021-06-17
Compositions and methods for inhibiting gene expression of Hif2alpha Grant 10,927,373 - Wong , et al. February 23, 2	2021-02-23
Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo App 20190062748 - Rozema; David B. ; et al.	2019-02-28
Biologically Cleavable Tetrapeptide Linking Agents App 20180258138 - Carlson; Jeffrey C. ; et al.	2018-09-13
Disubstituted maleic anhydrides with altered kinetics of ring closure Grant 10,059,681 - Blokhin , et al. August 28, 2	2018-08-28
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha App 20180230470 - Wong; So ; et al.	2018-08-16
Biologically cleavable tetrapeptide linking agents Grant 10,005,815 - Carlson , et al. June 26, 2	2018-06-26
Compositions and methods for inhibiting gene expression of Hif2alpha Grant 9,976,141 - Wong , et al. May 22, 2	2018-05-22
Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo App 20170022497 - Rozema; David B. ; et al.	2017-01-26
Biologically Cleavable Tetrapeptide Linking Agents App 20160347793 - Carlson; Jeffrey C. ; et al.	2016-12-01
Compositions and Methods for Inhibiting Gene Expression of Hif2alpha App 20160348107 - Wong; So ; et al.	2016-12-01
Polyconjugates for delivery of RNAi triggers to tumor cells in vivo Grant 9,487,556 - Cheng , et al. November 8, 2	2016-11-08
Disubstituted maleic anhydrides with altered kinetics of ring closure Grant 9,481,661 - Blokhin , et al. November 1, 2	2016-11-01
Disubstituted Maleic Anhydrides with Altered Kinetics of Ring Closure App 20160272605 - Blokhin; Andrei V. ; et al.	2016-09-22
Peptide-based in vivo siRNA delivery system Grant 9,107,957 - Rozema , et al. August 18, 2	2015-08-18
Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo App 20150045573 - Cheng; Weijun ; et al.	2015-02-12
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages Grant 8,802,773 - Rozema , et al. August 12, 2	2014-08-12
Disubstituted Maleic Anhydrides with Altered Kinetics of Ring Closure App 20140128584 - Blokhin; Andrei V. ; et al.	2014-05-08
Peptide-Based In Vivo siRNA Delivery System App 20130281658 - Rozema; David B ; et al.	2013-10-24
Peptide-based in vivo siRNA delivery system Grant 8,501,930 - Rozema , et al. August 6, 2	2013-08-06
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages Grant 8,426,554 - Rozema , et al. April 23, 2	2013-04-23
In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages App 20120172412 - Rozema; David B. ; et al.	2012-07-05
Peptide-Based In Vivo siRNA Delivery System App 20120165393 - Rozema; David B. ; et al.	2012-06-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.